Business Context and Reporting Period
This Form 10-Q covers Gilead Sciences, Inc. for the quarter and nine months ended September 30, 2001. Gilead is an independent biopharmaceutical company focused on infectious diseases and cancer. Key marketed products include AmBisome (antifungal), DaunoXome (cancer), and VISTIDE (cytomegalovirus). On October 26, 2001, the FDA approved Viread for HIV treatment, with initial shipments commencing immediately.
Key Financial Metrics
| Metric | Q3 2001 | Q3 2000 | 9M 2001 | 9M 2000 |
|---|---|---|---|---|
| Total Revenues | $50.9 million | $45.2 million | $159.4 million | $143.1 million |
| Net Loss | $(25.2) million | $(17.4) million | $(79.3) million | $(38.4) million |
| Net Loss Per Share | $(0.26) | $(0.19) | $(0.84) | $(0.42) |
| Operating Cash Flow | N/A | N/A | $(92.8) million | $(14.8) million |
| Cash & Equivalents (End) | $37.3 million | $43.4 million | $37.3 million | $43.4 million |
| Total Liquidity (Cash + Securities) | $440.6 million | N/A | $440.6 million | N/A |
| Convertible Notes Outstanding | $250.0 million | $250.0 million | $250.0 million | $250.0 million |
Accumulated Deficit: $585.3 million as of September 30, 2001.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 13% in Q3 and 11% in the first nine months of 2001 compared to 2000. Net product sales rose 20% in Q3, driven primarily by AmBisome (92% of product sales).
- Expense Increases: R&D expenses surged 29% in Q3 and 58% for the nine months, driven by Phase III trials for Viread (HIV) and adefovir dipivoxil (HBV), plus a $10.6 million upfront payment to Cubist Pharmaceuticals. SG&A expenses increased 50% in Q3 due to sales force expansion for the Viread launch.
- One-Time Gain: A non-operating gain of $8.8 million was recorded in Q3 from the sale of Gilead's 49% interest in Proligo L.L.C. for $14.3 million.
- Cash Position: Cash and cash equivalents decreased significantly from $197.3 million at year-end 2000 to $37.3 million at September 30, 2001, due to operating losses and capital expenditures, though total liquidity remains strong at $440.6 million including marketable securities.
Outlook, Risks, and Contingencies
- Guidance: Management expects full-year 2001 R&D expenses to be 35-45% higher than 2000 levels and SG&A expenses to be 45-55% higher, primarily due to Viread commercialization and late-stage development.
- Product Launch: Viread (tenofovir) received FDA approval in late October 2001. Market acceptance is uncertain, particularly for treatment-naive patients.
- Collaboration Risks: Revenue relies heavily on collaborations with Roche (Tamiflu) and Fujisawa (AmBisome). Tamiflu royalties declined in 2001 due to a mild flu season and inventory returns.
- Foreign Currency: A significant majority of sales are denominated in foreign currencies. A stronger U.S. dollar negatively impacts reported revenues and margins.
- Liquidity: The company believes existing capital resources are adequate for the foreseeable future but may require additional equity or debt financing if milestones are not met or development costs exceed expectations.
Investor Verification Checklist
- Viread Commercialization: Verify the pace of Viread sales uptake following its October 2001 launch and the associated SG&A burn rate.
- AmBisome Competition: Monitor market share retention for AmBisome against lower-priced competitors and new entrants.
- European Receivables: Review the collectibility of past-due accounts receivable in Greece, Spain, Portugal, and Italy, which totaled $25.8 million (with $9.8 million over 120 days past due).
- R&D Milestones: Track progress and costs of Phase III trials for adefovir dipivoxil (HBV) and the Cubist daptomycin collaboration.
- Convertible Notes: Assess the impact of the $250 million 5% convertible subordinated notes on future interest expense and potential dilution.